logo

For the Inventor, By the Inventor

Ebreichsdorf, Austria

Harald Engelhardt

This inventor holds 25 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Harald Engelhardt. Retrieved from https://idiyas.com/inventor/harald-engelhardt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 

% Patents Active = 96.0



Average Co-Inventor Count = 3.6

ph-index = 8

Forward Citations = 216(Granted Patents)


Location History:

  • Ingelheim am Rhein, DE (2013)
  • Eberichsdorf, AT (2015)
  • Ebreichsdorf, AU (2016)
  • Ebreichsdorf, AT (2007 - 2024)

Company Filing History:

goldMedal25 out of 1,562 
 
Boehringer Ingelheim International Gmbh
 patents

Years Active: 2007-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
EGFR Inhibitors
CDK8 Inhibitors
HER2 Inhibitors
BRD4 Inhibitors
Pyrimidines
Benzimidazole Compounds
Triazolopyrazine
Dihydroquinazolinone
Substituted Indolines
Phenylpyrazolylacetamide
Pyridinones
Chemical Compounds
25 patents (USPTO):Explore Patents
1. 12522615 - Macrocyclic compounds and derivatives as EGFR inhibitors (2026-01-13),
2. 12064421 - Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors (2024-08-20),
3. 11608343 - Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors (2023-03-21),
4. 11261184 - [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors (2022-03-01),
5. 11213520 - Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors (2022-01-04),
6. 11174245 - Benzimidazole compounds and derivatives as EGFR inhibitors (2021-11-16),
7. 11077107 - Triazolopyrazine (2021-08-03),
8. 10328074 - Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors (2019-06-25),
9. 9428515 - Benzimidazole derivatives (2016-08-30),
10. 9428513 - Triazolopyrazine (2016-08-30),
11. 9422290 - Triazolopyridazine (2016-08-23),
12. 9296748 - Pyridinones (2016-03-29),
13. 9266891 - Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors (2016-02-23),
14. 9199988 - Dihydroquinazolinone analogues (2015-12-01),
15. 9102684 - Indolinone analogues (2015-08-11),

Sure, here is the article about inventor Harald Engelhardt:

Title: The Innovative Mind of Harald Engelhardt in Ebreichsdorf, AT

Introduction:

Harald Engelhardt is a prolific inventor based in Ebreichsdorf, AT, with an impressive track record of 23 patents to his name. His groundbreaking work has significantly influenced the field of pharmaceuticals, particularly in the treatment and prevention of oncological diseases.

Latest Patents:

Engelhardt's latest patents include two significant innovations. The first is related to "Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors," showcasing his expertise in developing compounds that inhibit HER2 and its mutants. The second patent focuses on "[1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors," highlighting his dedication to creating novel solutions for the treatment of oncological diseases.

Career Highlights:

Harald Engelhardt is a valued member of the research and development team at Boehringer Ingelheim International GmbH. Through his innovative approach and dedication to scientific advancement, he has played a vital role in shaping the company's success in the pharmaceutical industry.

Collaborations:

Engelhardt has collaborated with esteemed colleagues such as Heinz Stadtmueller and Christian Smethurst. Together, they have contributed to revolutionary discoveries and have collectively advanced the boundaries of pharmaceutical research.

Conclusion:

In conclusion, Harald Engelhardt's contributions to the field of pharmaceuticals are truly remarkable. His inventive spirit and collaborative efforts continue to drive groundbreaking innovations in the development of novel medicaments for the treatment and prevention of oncological diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…